In a reversible middle cerebral artery occlusion mouse stroke model, the TfRMAb-TNFR also produced neuroprotection, causing a significant reduction in the hemispheric, cortical, and subcortical stroke volumes and neuronal deficit, whereas etanercept had no effect [107]. This evidence concerns the gene TNFRSF1A and stroke disorder.